Gallo-Oller, Gabriel
Pons, Guillem
Sansa-Girona, Júlia
Navarro, Natalia
Zarzosa, Patricia
García-Gilabert, Lia
Cabré-Fernandez, Paula
Guillén Burrieza, Gabriela
Valero-Arrese, Lorena
Segura, Miguel F.
Lizcano, José M.
Sánchez de Toledo, José
Moreno, Lucas
Gallego, Soledad
Roma, Josep
Article History
Received: 13 December 2023
Accepted: 17 March 2024
First Online: 5 April 2024
Declarations
:
: The experimental procedures were approved by the Ethics Committee of Animal Experimentation of the Vall d'Hebron Research Institute (CEEA 70/19) and were conducted in accordance with EU directive 2010/63/EU.
: Not applicable.
: L. Moreno is a member of a data monitoring committee for clinical trials sponsored by Novartis, Actuate Therapeutics, Shionogi, Incyte, the University of Southampton, and the Royal Marsden NHS Foundation Trust, and has a consulting role for Novartis and Shionogi (no direct compensation). L. Moreno is a member of the Executive Committee of SIOPEN (the European neuroblastoma research cooperative group), which receives royalties for the sales of dinutuximab beta. VHIR receives funding from sponsors for DMC participation, either in an advisory role or conducting industry-sponsored clinical trials. The rest of the team declares no conflict of interest.